Medicine and Dentistry
Ovarian Cancer
100%
Gynecological Oncology
66%
Neoplasm
50%
Organoid
44%
Uterine Cancer
40%
Chemotherapy
34%
Wound Complication
33%
Malignant Neoplasm
32%
Disease
29%
Female Genital Tract Cancer
25%
Metastatic Carcinoma
25%
Tumor Cell
25%
COVID-19
22%
Symptomatic Treatment
22%
Frailty Index
22%
Overall Survival
21%
Cell Line
19%
Homologous Recombination
17%
Patient Referral
16%
Cancer
16%
Hysterectomy
15%
Biological Marker
15%
Gynecological Surgery
14%
Immunohistochemistry
14%
DNA Repair
14%
Incision
13%
Recurrent Disease
13%
Poly ADP Ribose Polymerase
13%
Frailty
13%
Paclitaxel
12%
Mesothelial Cell
12%
DNA Damage
11%
Primary Tumor
11%
In Vitro
11%
Acute Chest Syndrome
11%
Immunofluorescence Test
11%
Direct Oral Anticoagulant
11%
Chlamydia Trachomatis
11%
Adipose Tissue
11%
Visceral Fat
11%
Gestagen
11%
Subcutaneous Fat
11%
Sickle Cell
11%
Immunotherapy
11%
Primary Health Care
11%
Cytoreductive Surgery
11%
End of Life Care
11%
Vulvar Cancer
11%
Drug Screening
11%
Trophoblastic Disease
11%
Keyphrases
Gynecologic Oncology
66%
Ovarian Cancer Patients
46%
Ovarian Cancer
43%
Endometrial Cancer
43%
Wound Complications
33%
High-grade Serous Ovarian Cancer (HGSOC)
32%
Gynecological Cancer
30%
Overall Survival
28%
Tumor Cells
28%
Oncology Patients
25%
AXL Inhibition
22%
Patient-derived Organoids
22%
Complication Rate
22%
COVID-19 Pandemic Impact
22%
Palliative Care
22%
Organoids
19%
Patient-derived
19%
Platinum-based Chemotherapy
18%
Survival Outcomes
17%
Gynecologic Malignancies
17%
Immunohistochemistry
16%
RAD51 Foci
16%
Treatment Options
16%
Tumor
15%
Predictive Biomarker
15%
Cancer Patients
15%
Hysterectomy
15%
Vulvar
14%
Ovarian Organoid
14%
Oncology Care
14%
Primary Tumor
14%
Society of Gynecologic Oncology
14%
Gynecologic Surgery
14%
Tumor Burden
14%
Vertical Incision
14%
Paclitaxel
13%
Chemotherapy Response
13%
Homologous Recombination Deficiency
13%
Ovarian Metastasis
13%
PARP Inhibitor (PARPi)
13%
Recurrent Endometrial Cancer
13%
Confidence Interval
12%
Sensitivity to Chemotherapy
12%
Uterine Serous Carcinoma
12%
Poor Prognosis
12%
Carboplatin
12%
Tumor Microenvironment
12%
COVID-19
12%
DNA Damage
12%
Replication Stress
12%